Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
08.09. | Dividendenbekanntmachungen (08.09.2025) | 6.742 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALPHABET INC CDR CA02080K1049 0,0341 CAD 0,0211 EUR ALPHABET INC CL A US02079K3059 0,21 USD 0,1791 EUR ALPHABET INC CL C US02079K1079 0... ► Artikel lesen | |
05.09. | LifeVantage falls after earnings miss, LoveBiome revenue outlook unclear | 2 | Seeking Alpha | ||
05.09. | LifeVantage outlines $225M-$240M FY26 revenue target amid LoveBiome acquisition and MindBody expansion | 2 | Seeking Alpha | ||
LIFEVANTAGE Aktie jetzt für 0€ handeln | |||||
04.09. | Earnings Call Transkript: LifeVantage übertrifft EPS-Prognose für Q4 2025, Aktie legt deutlich zu | 1 | Investing.com Deutsch | ||
04.09. | Lifevantage Corp Q4 Profit Increases, But Misses Estimates | - | RTTNews | ||
04.09. | Lifevantage-Aktie bricht ein: Umsatz im vierten Quartal verfehlt Analystenschätzungen | - | Investing.com Deutsch | ||
04.09. | LifeVantage Corporation: LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2025 | 72 | GlobeNewswire (Europe) | SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the... ► Artikel lesen | |
04.09. | Lifevantage Corp - 8-K, Current Report | 1 | SEC Filings | ||
04.09. | Lifevantage Corp - 10-K, Annual Report | 1 | SEC Filings | ||
03.09. | LifeVantage Q4 2025 Earnings Preview | 1 | Seeking Alpha | ||
03.09. | LifeVantage to acquire microbiome company LoveBiome | 1 | Investing.com | ||
03.09. | LifeVantage to acquire LoveBiome | 2 | Seeking Alpha | ||
03.09. | LifeVantage Corporation: LifeVantage Announces Acquisition of LoveBiome, Expanding Leadership in Direct Sales, Microbiome Health and Wellness | 1 | GlobeNewswire (USA) | ||
03.09. | What's Next: Lifevantage's Earnings Preview | 1 | Benzinga.com | ||
28.08. | LifeVantage Corporation: LifeVantage Declares Quarterly Dividend | 3 | GlobeNewswire (USA) | ||
21.08. | LifeVantage Corporation: LifeVantage to Announce Fourth Quarter and Full Fiscal Year 2025 Results on September 4, 2025 | 2 | GlobeNewswire (USA) | ||
22.07. | Studien: MindBody-System von LifeVantage steigert GLP-1-Spiegel um über 200 % | 1 | Investing.com Deutsch | ||
22.07. | LifeVantage reports 200% GLP-1 increase in MindBody system trials | 1 | Investing.com | ||
22.07. | LifeVantage Corporation: LifeVantage Announces Expanded Human Clinical Study for MindBody GLP-1 System; Findings Increase Average in Natural GLP-1 Production to Over 200%‡‡ | 179 | GlobeNewswire (Europe) | SALT LAKE CITY, July 22, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular... ► Artikel lesen | |
15.07. | LifeVantage Corporation: LifeVantage Hosts Activate 2025, Unveils New Quarterly Business Campaign and Incentive to Drive Global Growth | 2 | GlobeNewswire (USA) |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
GILEAD SCIENCES | 99,28 | +1,71 % | Veeva Systems: Gilead Sciences Commits to Veeva Vault CRM | Next generation CRM with deep capabilities and agentic AI
PLEASANTON, Calif., Sept. 10, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Gilead Sciences has committed... ► Artikel lesen | |
AURORA CANNABIS | 4,170 | +0,36 % | Aurora Cannabis Inc (3): Aurora, Copeia launch English medical cannabis system | ||
CANOPY GROWTH | 1,166 | +0,17 % | Canopy Growth Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
ABBVIE | 187,00 | +0,43 % | AbbVie, Atai Life Sciences und Neural Therapeutics: Deals im Milliarden-Markt für Psychedelika | ||
ELI LILLY | 640,30 | -0,76 % | Der nächste Schub steht an! NetraMark und BioNTech auf der Gewinnerspur, können Novo Nordisk und Eli Lilly folgen? | Künstliche Intelligenz (KI) transformiert die Entwicklung neuer Medikamente, indem sie komplexe Daten blitzschnell analysiert und klinische Studien effizienter gestaltet. Denn mit KI-Technologien werden... ► Artikel lesen | |
MERCK & CO | 70,70 | +0,14 % | Research and Markets: Europe Liver Disease Therapeutic Market Analysis Report 2025-2033 Featuring Abbott, Astellas, BMS, Gilead Sciences, GSK, F. Hoffman-La Roche, Merck & Co., Novartis, Sanofi, Pfizer, Takeda - ResearchAndMarkets.com | The "Europe Liver Disease Therapeutic Market Forecast 2025" report has been added to ResearchAndMarkets.com's offering.
The Europe Liver Disease Therapeutic Market is expected to grow from US$... ► Artikel lesen | |
TILRAY BRANDS | 0,963 | +0,67 % | Tilray Brands, Inc. - 8-K, Current Report | ||
TEVA | 17,050 | +0,29 % | Teva Pharmaceutical Industries Ltd: Teva's Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy | Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development.New... ► Artikel lesen | |
VERTEX PHARMACEUTICALS | 336,30 | +0,06 % | Vertex Pharmaceuticals Incorporated: Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis | Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Senior Vice President Paul Negulescu has been named as one of the winners of this year's Lasker~DeBakey Clinical Medical Research... ► Artikel lesen | |
ARZNEIWERK AG VIDA | 0,162 | +7,28 % | EQS-HV: Arzneiwerk AG VIDA: Bekanntmachung der Einberufung zur Hauptversammlung am 04.09.2025 in Berlin mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG | EQS-News: Arzneiwerk AG VIDA
/ Bekanntmachung der Einberufung zur Hauptversammlung
Arzneiwerk AG VIDA: Bekanntmachung der Einberufung zur Hauptversammlung am 04.09.2025 in Berlin... ► Artikel lesen | |
CRONOS GROUP | 2,170 | +0,84 % | Cronos Group Inc.: Cronos Group Reports 2025 Second Quarter Results | Net revenue in Q2 2025 increased by 21% year-over-year PEACE NATURALS® retained its position as the number one cannabis brand in Israel1 Highest-ever international and Israel revenue, fueled by strong... ► Artikel lesen | |
VIATRIS | 8,506 | +0,28 % | Dividendenbekanntmachungen (22.08.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABRDN AUSTRALIA EQUITY FUND INC US0030111035 0,12 USD 0,1033 EUR ACCO BRANDS CORPORATION US00081T1088 0,075 USD 0,0646 EUR ADM... ► Artikel lesen | |
EYEPOINT PHARMACEUTICALS | 11,435 | +0,44 % | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
INCYTE | 71,76 | +1,33 % | Incyte stellt neue Daten vor, die Fortschritte im Dermatologie-Portfolio auf dem European Association of Dermatology and Venereology 2025 Congress hervorheben | 24-Wochen-Daten aus dem Phase-3-Studienprogramm STOP-HS zu Povorcitinib bei Patienten mit Hidradenitis suppurativa (HS) wurden als Late-Breaking-Oral-Präsentation ausgewählt
Heute gab Incyte (Nasdaq:... ► Artikel lesen | |
BAUSCH HEALTH | 6,200 | +0,16 % | Bausch Health Companies Inc.: Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio | The transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis with a registrational Phase 3 clinical trial in development, to Bausch Health's hepatology pipeline LAVAL... ► Artikel lesen |